NCT02480036
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 50 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: 
Exclusions: Patients who have had prior radiation therapy or surgery in the area of planned intervention
https://ClinicalTrials.gov/show/NCT02480036